Transcriptional control: an essential component of cancer gene therapy strategies? (Q34079558)

30 July 2017

1 reference

title

Transcriptional control: an essential component of cancer gene therapy strategies? (English)

1 reference

30 July 2017

0 references

1 reference

Harrington KJ

1

1 reference

30 July 2017

Linardakis E

series ordinal

2

1 reference

30 July 2017

Vile RG

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

Advanced Drug Delivery Reviews

30 July 2017

1 reference

30 July 2017

44

1 reference

30 July 2017

2-3

1 reference

30 July 2017

167-184

1 reference

Progress in transcriptionally targeted and regulatable vectors for genetic therapy

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Viral vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Development and application of adenoviral vectors for gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Nonviral gene therapy: promises and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Relative activity and specificity of promoters from prostate-expressed genes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

In vivo expression of prostate-specific adenoviral vectors in a canine model

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Telomeres, telomerase, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Eradication of murine mammary adenocarcinoma through HSVtk expression directed by the glucose-starvation inducible grp78 promoter.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Targeting gene expression to hypoxic tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

New perspectives in clinical oncology from angiogenesis research

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Antiangiogenesis for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Cell type specificity of the human endoglin promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Controlling mammalian gene expression with small molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tetracycline-responsive expression system.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Inducible long-term gene expression in brain with adeno-associated virus gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Tetracycline-reversible silencing of eukaryotic promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Transcriptional activation by tetracyclines in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Adenovirus-mediated regulable target gene expression in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Ligand-dependent regulation of plasmid-based transgene expression in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Ecdysone-inducible gene expression in mammalian cells and transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Pharmacologic control of a humanized gene therapy system implanted into nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Long-term regulated expression of growth hormone in mice after intramuscular gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

A humanized system for pharmacologic control of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Biological consequences of gene regulation after ionizing radiation exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Radiation induction of immediate early genes: effectors of the radiation-stress response.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Spatial and temporal control of gene therapy using ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Ionizing radiation activates transcription of the EGR1 gene via CArG elements

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Induction of the suicide HSV-TK gene by activation of the Egr-1 promoter with radioisotopes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Heat-inducible vectors for use in gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Control of transgene expression using local hyperthermia in combination with a heat-sensitive promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

On the feasibility of MRI-guided focused ultrasound for local induction of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Gene therapy: designer promoters for tumour targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Transcriptional Regulatory Sequences of Carcinoembryonic Antigen: Identification and Use with Cytosine Deaminase for Tumor-Specific Gene Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Liver-directed gene therapy: evaluation of liver specific promoter elements

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector--potential glioblastoma targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: myelin basic protein promoter is strongly active in human malignant glioma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Hepatoma-specific gene therapy through retrovirus-mediated and targeted gene transfer using an adenovirus carrying the ecotropic receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Engineering tissue-specific expression of a recombinant adenovirus: selective transgene transcription in the pancreas using the amylase promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2800%2900093-4

7 January 2021

10.1016/S0169-409X(00)00093-4

Identifiers

DOI

1 reference

30 July 2017

1 reference